Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | CheckMate 227 update

Sanjay Popat • 29 Sep 2019
ESMO 2019
Lung Cancer Non-Small Cell Lung Cancer Ipilimumab Nivolumab
CheckMate 227

Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHS Foundation Trust, London, UK, gives an update on the CheckMate 227 (NCT02477826), investigational immuno-therapy trial of nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy, compared to platinum doublet chemotherapy in patients with stage IV Non-Small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Sanjay Popat

0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023
0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023
1:21
SYSTEMS-2: Radiotherapy and potential survival benefits in mesothelioma
Sanjay Popat • 29 Apr 2023
2:18
Highlights from BTOG 2023
Sanjay Popat • 28 Apr 2023

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals